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The Saccharomyces cerevisiae genes TORI and TOR2 were originally identified by mutations
that confer resistance to the immunosuppressant rapamycin. TOR2 was previously shown
to encode an essential 282-kDa phosphatidylinositol kinase (PI kinase) homologue. The
TORI gene product is also a large (281 kDa) PI kinase homologue, with 67% identity to
TOR2. TORI is not essential, but a TORI TOR2 double disruption uniquely confers a cell
cycle (Gi) arrest as does exposure to rapamycin; disruption of TOR2 alone is lethal but
does not cause a cell cycle arrest. TOR1-TOR2 and TOR2-TOR1 hybrids indicate that
carboxy-terminal domains of TOR1 and TOR2 containing a lipid kinase sequence motif
are interchangeable and therefore functionally equivalent; the other portions of TOR1 and
TOR2 are not interchangeable. The TORI-I and TOR2-1 mutations, which confer rapamycin
resistance, alter the same potential protein kinase C site in the respective protein's lipid
kinase domain. Thus, TOR1 and TOR2 are likely similar but not identical, rapamycin-
sensitive PI kinases possibly regulated by phosphorylation. TOR1 and TOR2 may be com-
ponents of a novel signal transduction pathway controlling progression through G1.
INTRODUCTION
The immunosuppressive drug rapamycin causes yeast
cells and activated T cells to arrest in the Gl phase of
the cell cycle (Heitman et al., 1992; Sigal and Dumont,
1992; Schreiber and Crabtree, 1992). In the yeast Sac-
charomyces cerevisiae, the three genes FPR1, TORI, and
TOR2 are involved in the action of rapamycin. Muta-
tions in any one of these genes renders yeast cells re-
sistant to the toxic effects of the drug (Heitman et al.,
1991a). FPR1 is a nonessential cytosolic FK506-binding
protein (FKBP) that also binds the FK506 analogue ra-
pamycin (Heitman et al., 1991b; Koltin et al., 1991;
Wiederrecht et al., 1991). FKBPs are highly conserved,
ubiquitous proteins that have proline isomerase activity
in vitro and may fold proteins in vivo. TOR2 is an es-
sential phosphatidylinositol kinase (PI kinase) homolog
(Kunz et al., 1993). Cells lacking TOR2 are nonviable
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but arrest randomly in the cell cycle. As described below,
TOR1 is a nonessential PI kinase homologue, however,
cells lacking both TOR1 and TOR2 arrest in Gl (Kunz
et al., 1993). Thus, the TOR gene products appear to be
components of a novel signal transduction pathway that
controls progression through the Gl phase of the cell
cycle. The current model for drug action is that a FKBP-
rapamycin complex gains a toxic function that blocks
cell proliferation by inhibiting TOR1 and TOR2 (Kunz
and Hall, 1993).
Phosphatidylinositol (PI) kinases phosphorylate the
inositol ring of PI (for review see Carpenter and Cantley,
1990). PI 4-kinases (type II and III PI kinase) phos-
phorylate the 4 position of the inositol ring, to produce
PI-4-P. PI-4-P is then phosphorylated on the 5 position
to produce PI-4,5-P2, which is subsequently cleaved by
phospholipase C to form the standard second messen-
gers diacylglycerol (DAG) and inositol-1,4,5-trisphos-
phate (1P3) (Berridge, 1987; Berridge and Irvine, 1989).
PI 4-kinase has been detected in various tissues (Hou
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et al., 1988; Walker et al., 1988; Porter et al., 1989), and
three PI 4-kinases have been purified and characterized
from yeast (Buxeda et al., 1991; Nickels et al., 1992;
Flanagan and Thomer, 1992). PI 3-kinase (type I Pl-
kinase) adds phosphate to the 3 position of the inositol
ring of PI, PI-4-P, and PI-4,5-P2. In mammalian cells,
it appears that at least one of the products of PI 3-
kinase, PI-3-P, PI-3,4-P2, and PI-3,4,5-P3, acts directly
as a second messenger signaling cell proliferation. First,
3-phosphorylated phosphoinositides are not substrates
for phospholipase C (Lips et al., 1989; Serunian et al.,
1989). Second, active PI 3-kinase is associated with ac-
tivated tyrosine kinases, and in the case of the platelet-
derived growth factor receptor, PI 3-kinase is an inde-
pendent downstream mediator of the PDGF mitogenic
signal (Cantley et al., 1991; Valius and Kazlauskas,
1993). Third, the kinetics of appearance of 3-phos-
phorylated phosphoinositides in PDGF-stimulated cells
is consistent with a role as a second messenger (Auger
et al., 1989b). Fourth, the r isozyme of bovine protein
kinase C (PKC) can be activated by PI-3,4-P2 and Pl-
3,4,5-P3 (Nakanishi et al., 1993).
In yeast, the ratio of endogenous PI-3-P to PI-4-P is
approximately 60:40, in stark contrast to mammalian
cells where the ratio is approximately 10:90 (Whitman
et al., 1988; Auger et al., 1989a; Stephens et al., 1989;
Hawkins et al., 1993). The yeast PI 3-kinase VPS34 is
involved in the sorting of soluble vacuolar proteins. A
VPS34 disruption strain is temperature sensitive for
growth and exhibits severe defects in the sorting of vac-
uolar carboxypeptidase Y, and, in addition, has no de-
tectable PI-3-P (Herman and Emr, 1990; Schu et al.,
1993). Thus, in yeast, 3-phosphorylated phosphoino-
sitides have a role in membrane traffic.
The TOR2 gene encodes a 282-kDa protein with ho-
mology to the pllO catalytic subunit of bovine phos-
phatidylinositol 3-kinase and VPS34 (Herman and Emr,
1990; Hiles et al., 1992; Kunz et al., 1993). The region
of highest homology between the three proteins con-
stitutes a lipid kinase consensus sequence (Kunz et al.,
1993). In the case of VPS34, the lipid kinase motif is
required for PI 3-kinase activity (Schu et al., 1993).
Here we describe the isolation and characterisation
of the TORI gene. The gene is 68 and 67% identical to
TOR2 at the nucleotide and predicted amino acid level,
respectively, and also contains a so-called lipid kinase
domain. Because disruption of TORI and TOR2 indi-
vidually and disruption of TORI and TOR2 in combi-
nation all confer different phenotypes, TOR1 and TOR2
have overlapping and distinct functions. TOR2-TOR1
and TOR1-TOR2 hybrid proteins suggest that a shared
cell cycle function is mediated by each intact protein's
highly conserved (80% identity) carboxy-terminal lipid
kinase domain. Furthermore, the lipid kinase domain
of TOR1 and TOR2 may be a target of PKC, as suggested
by mutations that confer rapamycin resistance.
MATERIALS AND METHODS
Strains, Plasmids and Media
The S. cerevisiae strains used in this work are listed in Table 1. All
strains except the tif2, stel8, and pkcl strains were isogenic JK9-3d
derivatives. SH8 was constructed by crossing NB3-3b with NB6-4c
and selecting against the pJK3-3 plasmid. YCplacl 11 is CEN4 LEU2
ampr (Gietz and Sugino, 1988). pSEY18 is 2M URA3 ampr (from S.
Emr, University of California, San Diego). Plasmid pPW2 is pSEY18
carrying a 16-kilobase kb genomic DNA insert containing the TORI-
1 allele (see Construction of Genomic DNA Library). Plasmid pPW2-13
is pPW2 lacking the 9-kb Bgl II fragment of the genomic DNA insert.
Plasmid pPW20 is a gap-repaired derivative of pPW2-13 containing
the wild-type TORI allele (see Cloning of TOR1). Plasmid pJK3-3 is
pSEY18 containing the wild-type TOR2 allele (Kunz et al., 1993).
Plasmid pJK4 is YCplacl 11 containing TOR2 (Kunz et al., 1993). Plas-
mid pJK5 is CEN4 URA3 GALlp-TOR2 amp7 (Kunz et al., 1993). Plasmid
pTORl-TOR2 is YCplaclll carrying the TOR1-TOR2 hybrid gene.
Plasmid pTOR2-TOR1 is YCplacl 11 containing the TOR2-TOR1 hy-
brid gene. The pTORl-TOR2 and pTOR2-TOR1 plasmids were made
as described below (see Construction of TOR1-TOR2 and TOR2-TORI
Hybrid Genes). Plasmid pBM743[PKCi] (D. Levin, The Johns Hopkins
University, Baltimore) is CEN URA3 GAL1p-PKClamp'. The compo-
sition of rich medium (YPD), synthetic minimal medium (SD, SGalGly)
complemented with the appropriate nutrients for plasmid mainte-
nance, and sporulation medium were as described (Sherman, 1991).
YPlactate, YPpyruvate, and YPglycerol were prepared as described
(Davis et al., 1992), with the exception that YPglycerol contained 3%
glycerol and 3% ethanol. Medium containing 1 M sorbitol was YPD.
Rapamycin (kindly provided by Sandoz Pharma Ltd., Basel) was added
to the medium to a final concentration of 0.2 ,g/ml. Before addition
to media, the drug was dissolved (1 mg/ml) in 10% Tween-20 in
ethanol.
Table 1. Yeast strains used in this study
DL164
JH3-3b
JH1 1-lc
JK9-3da/a
JK9-3da
JK9-3da
JK350-2a
JK350-3a
MH269-4d
MH272-lc
MH272-lda
MH272-3fa/a
MH272-3fa
MH272-3fa
MH349-3b
MH349-3d
MH350-la
MH350-ld
MH353-2b
MH353-2c
NB3-3b
NB6-4a
NB6-4c
Rl
R17
SH8
SS4
358/pSTE18
a trpl leu2 ura3 his4 canl pkcl::LEU2
JK9-3da fprl:: URA3-3
JK9-3da TORI-i
a/a leu2-3,112/leu2-3,112 ura3-52/ura3-52 trpl/
trpl his4/his4 rmel/rmel HMLa/HMLa
a leu2-3,112 ura3-52 trpl his4 rmel HMLa
a leu2-3, 112 ura3-52 trpl his4 rmel HMLa
JK9-3da ade2A torl::LEU2-4 tor2::ADE2-3
JK9-3da ade2A tor2::ADE2-3
JK9-3da ade2A fprl::URA3-3
MH272-3fa fprl:: URA3-3
JK9-3da HIS4 his3A
JK9-3da/a HIS4/HIS4 his3A/his3A ade2X/Iade2A
JK9-3da HIS4 his3A ade2A
JK9-3da HIS4 his3A ade2A
JK9-3da torl::LEU2-4
JK9-3da torl::LEU2-4
JK9-3da torl::LEU2-5
JK9-3da torl::LEU2-5
MH272-3fa torl: :ADE2-6
MH272-3fa torl: :ADE2-6
MH272-3fa tor2::ADE2-3/pJK3-3
MH272-3fa torl: :HIS3-3
MH272-3fa torl::HIS3-3
JK9-3da TORI-I
JK9-3da TOR2-1
MH272-3fa/a torl: :HIS3-3/TORi tor2: :ADE2-
3/TOR2
a leu2 ura3 trpl his3 ade2 Atif2::URA3
a leu2 ura3 trpl his stel8::LEU2/pSEY18::STE18
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General Genetic Manipulations
Standard genetic techniques of crossing, sporulation, and tetrad anal-
ysis were as described (Guthrie and Fink, 1991). S. cerevisiae trans-
formation was performed by the lithium acetate procedure (Ito et al.,
1983). Escherichia coli strains MH1 or DH5a were used for propagation
and isolation of plasmids as described (Sambrook et al., 1989).
Construction of Genomic DNA Library
Total genomic DNA from the S. cerevisiae strain Ri was isolated as
described (Philippsen et al., 1991) and subjected to partial Sau3A
digestion. Fragments were fractionated on a 0.8% low-melting agarose
gel and ligated into the BamHI site of pSEY18. The ligation mixture
was transformed into E. coli strain MH1. Independent transformants
(20 000) were pooled and plasmid DNA was isolated. The mean insert
size was 12 kb and insert frequency was >80%. The six positive clones
isolated from this library were named pPW2, pPW6, pPWl 1, pPW13,
pPW14, and pPW15. Subsequently, pPW2 and pPW14 were found
to be identical, as were pPW6 and pPW11.
Cloning of TOR1
The TORI-i gene was cloned by using the semidominant rapamycin-
resistance phenotype conferred by this mutant allele at 30 and 37°C.
JK9-3da/a diploid wild-type cells were transformed with the yeast
genomic library constructed from the TORI-1 mutant strain R1 in the
vector pSEY18. Several genome equivalents of Ura+ transformants
selected at 37°C on minimal plates lacking uracil (SD-Ura) were replica
plated at 37°C to prewarmed SD-Ura plates containing rapamycin
(0.2 Ag/ml). Rapamycin-resistant replica colonies were picked, and
the plasmid DNA was isolated (Hoffman and Winston, 1987). After
amplification in E. coli, the plasmid DNA was reintroduced into the
original yeast strain JK9-3da/a and plasmid-dependent resistance to
rapamycin at 37°C was confirmed on selective plates containing ra-
pamycin (0.2 ,g/ml). To clone the wild-type TORI gene by gap repair
(Rothstein, 1991), plasmid pPW2-13 (Figure 1A) was linearized with
Bgl II and transformed into the wild-type strain JK9-3da. Plasmids
from several independent Ura+ transformants were reisolated and
mapped by restriction analysis to confirm the gap repair. For integrative
mapping, plasmid pPW2 was linearized at the Bgl II site within the
genomic DNA insert and transformed into strain JK9-3da. Ura+
transformants were selected on minimal plates and tested for sensitivity
to 5-fluoro-orotic acid, indicative of stable integration of the plasmid.
Integrants were subsequently crossed to strain JH1 1-ic. The resultant
diploids were sporulated and meiotic segregants were tested for seg-
regation of the URA3 and TORi-i genes. Rapamycin resistance was
used as a marker for the TORI-i allele, and uracil prototrophy was
used as a marker for the integrated plasmid. Twenty four tetrads were
analyzed.
Mapping the Chromosomal Site of TOR1
The 6.8-kb internal Kpn I fragment of plasmid pPW20 was used as a
probe for hybridization to a set of overlapping X-based genomic clones
(gift of L. Riles and M. Olson, Washington University, St. Louis).
Hybridization was done according to the recommendations of L. Riles.
For meiotic mapping, strain Ri (TORI-1) was crossed to strains SS4
(tif2::URA3) and 358/pSTE18 (ste18::LEU2); resultant diploids were
sporulated and dissected, and the segregation pattern of URA3 (tif2),
LEU2 (ste18), and rapamycin resistance (TORI-1) was followed.
Plasmids for Deletion Analysis
Plasmids for deletion analysis were obtained by cutting plasmid pPW2
(TORI-1) at sites that were present in both the polylinker and in the
insert (or multiple times within the insert) and religating. Alternatively,
restriction fragments were subcloned into the multi-copy vector
YEplacl81, 2,u LEU2 ampr (Gietz and Sugino, 1988). Plasmids listed
in Figure 1A were all derived from plasmid pPW2 (except for pPW15)
and represent the following deletions and subclones (there are Sal I,
Sph I, Xho I, HindIII and BamHI sites in the polylinker of pSEY18 at
the left end of the insert, and Sac I and Kpn I sites in the polylinker
at the right end of the insert of pPW2): pPW2-2, ASal I deletion;
pPW2-6, ASph I deletion; pPW2-7, AHindIII deletion; pPW2-8,
ABamHI deletion; pPW2-9, AXho I deletion of pPW2-2; pPW2-10,
ASac I deletion; pPW2-1 1, AXho I deletion; pPW2-12, AKpn I deletion;
pPW2-13, ABglII deletion; pPW2-3, the 2.6 kb Kpn I fragment was
cloned into pSEY18, which was recut with BamHI (in the polylinker)
and Bgl II (within the Kpn I fragment) and ligated with the 9-kb Bgl
II fragment of pPW2; pPW2-4, constructed as described for pPW2-3
but starting with the 1-kb HindIII fragment; pPW2-5, the 9-kb Bgl II
fragment was inserted into the BamHI site of pSEY18. Plasmids were
tested for their ability to confer rapamycin resistance on an otherwise
sensitive strain JK9-3da.
TOR1 Disruption
The TORI disruption vector pMD19 was constructed by cutting pPW20
with Sal I and religating (making pPW20-1), followed by replacement
of 4 kb and 140 basepair (bp) BamHI fragments with a 2.3-kb Bgl II
fragment containing the LEU2 gene. Plasmid pNB6 was constructed
in a similar manner, except that a 1.8-kb Bgl II fragment containing
the HIS3 gene was used in place of the LEU2 insert. Plasmid pMD18
was constructed by cloning the 4-kb HindIII fragment from pPW20
into pSEY18 and inserting a 2.2-kb Xho I-Sal I fragment containing
the LEU2 gene in the unique Xho I site in the insert. Plasmid pMD16
was constructed by cloning the 5.7-kb BamHI fragment from pPW20
into pGEM7Zf(+) (Promega, Madison, Wisconsin) and inserting a 2.2-
kb Bgl II ADE2 gene cassette into the unique Bgl II site of the insert.
The disruption cassettes were excised from pMD19 (torl::LEU2-4)
and pMD18 (torl::LEU2-5) by cutting with Bgl II and HindIII, re-
spectively, and were transformed into JK9-3da/a, selecting for Leu+.
The pMD16 disruption cassette (torl ::ADE2-6) was excised with BamHI
and transformed into MH272-3fa/a, selecting for Ade+. The pNB6
disruption cassette (torl::HIS3-3) was excised with Bgl II and trans-
formed into MH272-3fa/a, selecting for His'. The successful disrup-
tion of the chromosomal TORI locus was verified in transformants
by Southern analysis. Diploid strains that showed the expected hy-
bridization pattern were designated MH349 (tori::LEU2-4/TORl),
MH350 (tori ::LEU2-5/TOR1), MH353 (torl ::ADE2-6/TORi), and NB6
(torl::H1S3-3/TORi). These strains were sporulated, and 16 tetrads
each from strains MH349, MH350, MH353, and NB6 were dissected.
TOR Depletion and Analysis of DNA Content
by Flow Cytometry
Haploid strains JK9-3da (TORI TOR2), MH349-3d (torl TOR2), JK350-
3a (TORI tor2), and JK350-2a (torl tor2), all containing pJK5 (a CEN4
URA3 plasmid containing TOR2 under control of the GALI promoter)
(Kunz et al., 1993), were grown in liquid SGalGly-Ura medium. Cells
were then used to inoculate SD-Ura (glucose) medium at an OD600 of
0.02 and incubated for 16 h at 30°C. In glucose medium, expression
of the plasmid-borne TOR2 is repressed and, because TOR2 is essential,
TORI tor2 and torl tor2 strains arrested growth in early log phase.
The TOR2 cells continued to grow, but were still in log phase when
harvested. Three hundred microliters of cells were chilled on ice, son-
icated for 2 min in a water bath sonicator, and diluted in 700,l cold
absolute ethanol. After shaking overnight at 4°C, the cells were cen-
trifuged briefly, washed once in 50 mM sodium citrate pH 7.4, and
resuspended in 500 ttl 50 mM sodium citrate pH 7.4 containing RNase
A at 0.25 mg/ml. After incubating 1 h at 37°C, 500 gl of 50 mM
sodium citrate, 16 ,tg/ml propidium iodide was added. A Becton-
Dickinson FACScan machine (Lincoln Park, NJ) was used to measure
fluorescence, and 10 000 events were analyzed for each strain.
Construction of TOR1-TOR2 and TOR2-TOR1
Hybrid Genes
The pTOR1-TOR2 plasmid was constructed by cutting the vector pJK4
with Sac I and BamHI, and replacing the excised region with a 7.8-
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kb Sac I-BamHI fragment of pPW20 containing the promoter and
codons 1-1680 of TORI. To obtain the 7.8-kb Sac I-BamHI fragment,
pPW20 (pSEY18::TORI) was first cut with Sal I and religated (to
remove other Sac I and BamHI sites 3' of the desired region) and then
subjected to a Sac I digest, followed by a BamHI partial digest. The
partial digest was loaded onto low melting agarose and, after electro-
phoresis, the relevant band was excised and ligated into the prepared
vector as described (Sambrook et al., 1989). The pTOR2-TOR1 plasmid
was made by excising the 4.4-kb BamHI-Sal I fragment from plasmid
pJK4 and replacing it with the 4.8-kb BamHI-Sal I fragment from
pPW20 containing codons 1681-2470 and the 3'-end of TORI.
DNA Manipulations
Recombinant DNA manipulations were performed according to stan-
dard methods (Sambrook et al., 1989). The DNA probes for Southern
analysis were labelled using the random-primed labelling kit (Amer-
sham International, Bucks, UK) following the manufacturer's rec-
ommendation. DNA probes for the physical mapping of the TORI
gene were made by random-primed 32P-labelling using random hex-
anucleotides as primers, [a-32P]dATP, and the Klenow fragment of
DNA polymerase I. Total yeast genomic DNA for Southern analyses
was extracted as described (Guthrie and Fink, 1991), fractionated by
gel electrophoresis on an agarose gel in Tris borate EDTA (TBE) and
transferred to nylon membranes. Hybridization was according to the
manufacturer's recommendation (Amersham International). For se-
quencing, restriction fragments were cloned into the vector
pGEM7Zf(+) (Promega) and sets of nested deletions were obtained
by the exonuclease III method using the Erase-a-Base system (Pro-
mega). Custom-made oligonucleotides were used as primers for se-
quencing regions not accessible with the deletions. DNA sequencing
was performed by the dideoxy chain-termination method (Sanger et
al., 1977) using the T7 sequencing system from Pharmacia (Piscataway,
NJ). To determine the sequence of the TORI-i mutation, a 4.0-kb
HindIll fragment containing the region of interest (Figure 1A) was
cloned into pSEY18 for use as a template. To determine the sequence
of the TOR2-1 mutation, a 1.2-kb Sal 1-HindIII fragment of the relevant
region was cloned for use as a template.
RESULTS
Isolation of TOR1
The TORI-i mutant allele confers resistance to rapa-
mycin and is semidominant at 30 or 37°C and recessive
at 24°C. The TORI gene was isolated using a strategy
identical to that used to isolate TOR2 (Kunz et al., 1993)
in which the mutant allele was cloned first by taking
advantage of the dominant rapamycin resistant phe-
notype at high temperature. A library was constructed
from TORi-i mutant strain Rl in the multicopy vector
pSEY18 (2,u URA3) and transformed into JK9-3da/a.
Ura+ transformants were selected at 37°C and screened
on solid minimal media lacking uracil and containing
rapamycin at a concentration of 0.2 ,ug/ml. Plasmids
that conferred growth at 37°C on medium containing
rapamycin were isolated. Four different plasmids,
pPW2, pPW6, pPW13, and pPW15, were obtained from
among six that contained overlapping genomic inserts
able to confer resistance to rapamycin. Plasmids pPW2
and pPW15 containing the smaller inserts, 16 and 15
kb respectively, were chosen for further characteriza-
tion. The restriction map of the pPW2 insert and the
overlapping region of the pPW15 insert are shown in
Figure 1A. pPW15 is denoted in Figure 1A as giving
partial resistance (+/-) because transformants with this
plasmid did not grow in the presence of rapamycin as
well as transformants with the other three plasmids.
The insert of pPW2 was shown to correspond to the
TORI locus by integrative mapping (see MATERIALS
AND METHODS).
The wild-type TORI gene was isolated by gap repair
of the cloned mutant allele. Plasmid pPW2-13, pPW2
lacking the internal 9-kb Bgl II fragment (Figure 1A),
was linearized with Bgl II and transformed into wild-
type strain JK9-3d. Plasmids from Ura+ transformants
were isolated and amplified in E. coli. A typical recovered
plasmid, pPW20, was identical by restriction analysis
to pPW2 (Figure 1A) but, unlike pPW2, was unable to
confer rapamycin resistance. Thus, gap-repaired plas-
mid pPW20 contained the wild-type TORI allele. This
was further confirmed by the subsequent demonstration
(see below) that the TORi-i lesion is a single base pair
change (Figure 2) within the Bgl II fragment deleted for
the gap repair.
Physical and Genetic Mapping of TOR1
To determine the map position of TORI, the internal
6.8-kb Kpn I fragment (Figure 1A) derived from pPW20
was radiolabeled and used to probe an ordered X-based
S. cerevisiae library. Two clones, one corresponding to
a position - 100 kb centromere-proximal to TIF2 on the
left arm of chromosome X and the other corresponding
to a position -25 kb centromere-proximal to STE18 on
the right arm of the same chromosome, were detected.
To further define the map position of TORI, strain Rl
(TORI-i) was crossed to strain SS4 (tif2::URA3) and
strain 358/pSTE18 (stel8::LEU2). Sporulated diploids
were dissected, and segregation of the relevant markers
was checked. On the basis of a parental ditype:non-
parental ditype:tetratype ratio of 28:0:11, TORI was
found to be 14.1 cM centromere-proximal to STE18. No
linkage was detected between TORI and TIF2.
TOR1 Is Homologous to TOR2 and PI 3-kinases
The position of the TOR1 gene in the 16-kb insert of
pPW2 was located by testing the ability of different
deletion constructs to confer rapamycin resistance when
transformed into a wild-type strain. As illustrated in
Figure 1A, an -11-kb region extending from the left
most Bgl II site to beyond the right most Kpn I site was
required to provide full rapamycin resistance. The nu-
cleotide sequence of this region from plasmid pPW20
containing the wild-type TORI allele was determined.
The sequence revealed a 7410 nucleotide open reading
frame (ORF) (Figure 2) whose ends are in good agree-
ment with the boundaries defined by the deletion anal-
ysis. Furthermore, Northern analysis using the internal
4.2-kb HindIII fragment as a probe detected a message
of 8 kb that disappeared in a TORI disruption strain.
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Figure 1. Restriction map of TORI, functional assay of deletion constructs, and TOR1 disruptions. (A) Plasmid pPW2, pPW15 and derivatives
containing the DNA indicated by a line were tested for ability to confer rapamycin resistance when transformed into wild-type strain JK9-
3da/a. (+) and (-) indicate ability and inability, respectively, to confer rapamycin resistance. =* indicates the position of the TORI ORF as
determined by DNA sequence analysis. Restriction enzyme sites are abbreviated as follows: B, BamHI; Bg, Bgl II; K, Kpn I; X, Xho I; C, Cla I;
H, HindIII; Sp, Sph I; S, Sal I; Sc, Sac I. BamHI and Sal I sites to the right of the right-most indicated Sal I site have been omitted. (B) TORi
disruptions. torl ::HIS3-3 and torl ::LEU2-4, a LEU2 or HIS3 cassette was inserted as a Bgl II fragment into a BamHI deletion of the coding
region. torl ::LEU2-5, an Xho I-Sal I LEU2 fragment was inserted into the a Xho I site in the coding region. torl ::ADE2, a Bgl II ADE2 cassette
was inserted into the Bgl II site in the lipid kinase sequence motif.
Thus, TOR1 is a protein of 2470 amino acids with a
calculated molecular weight of 281 kDa and a predicted
pI of 7.33.
TOR1 is remarkably similar to TOR2 (2474 amino
acids). A comparison of the sequences of the TORI and
TOR2 genes revealed 68% identity at the nucleotide
level and 67% identity for the predicted amino acid
sequences (Figures 3 and 5). TOR1, like TOR2, is also
related to the pllO catalytic subunit of bovine PI 3-
kinase and the yeast PI 3-kinase VPS34 (Herman and
Emr, 1990; Hiles et al., 1992). Amino acids 1240-2441
of TOR1 are 22.3% identical and 47.8% similar to
VPS34 (875 amino acids). Amino acids 901-2435 of
TOR1 are 20.3% identical and 45.6% similar to pllO
(1068 amino acids). Furthermore, the carboxy-terminal
halves of all four proteins contain a lipid kinase motif
(Figures 2 and 3) (Kunz et al., 1993). The lipid kinase
motif is within amino acids 2123-2296 of TOR1 and
amino acids 2127-2300 of TOR2 (Figure 3). Thus, TOR1
is a PI 3-kinase homologue as is TOR2.
TOR1 contains a Ca2+-dependent lipid-binding
(CaLB) domain. The CaLB domain is a sequence motif
originally identified as a conserved region in the Ca2-
dependent isozymes of mammalian PKC (a, and 'y)
and in phosphoinositidase C, and more recently impli-
cated in the Ca2"-dependent binding of cytosolic phos-
pholipase A2 to membranes (Baker, 1989; Clark et al.,
1991). A CaLB domain is also found in TOR2, pllO
and several other cytosolic proteins (but not VPS34)
that may be activated by Ca2" to act on or utilize mem-
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Figure 2. Nucleotide sequence
of TORI and deduced amino acid
sequence. Complete nucleotide
sequence of the TORI ORF and
adjacent 5 and 3' sequence. The
deduced amino acid sequence is
denoted using the one letter
code. The position of the lipid
kinase motif is indicated with
continuous lines underneath the
amino acid sequence (within
amino acids 2123-2296). Indi-
vidually underlined residues
correspond to the CaLB domain
(within amino acids 1522-1629).
The position of the BamHI re-
striction enzyme recognition site
(GGATCC), used in the con-
struction of hybrids (Figure 5), is
indicated. The nucleotide (C) and
amino acid (R) in parentheses at
positions 6215 and 1972, re-
spectively, indicate the changes
introduced by the TORI-i mu-
tation.
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Figure 3. TOR1 is highly ho-
mologous to TOR2. The pre-
dicted amino acid sequences of
TOR1 (top) and TOR2 (bottom)
were aligned using the Bestfit
program (Genetics Computer
Group package, Devereux et al.,
1984). A vertical line between
two amino acids indicates iden-
tity; two dots represent a con-
servative difference. The lipid
kinase motif is indicated by
continuous lines underneath the
sequences. Conserved amino
acids of the CaLB domain are
underlined individually. The
potential PKC site (SR) altered
in TORl-1 and TOR2-i is
boxed.
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brane phospholipids (Clark et al., 1991; Stephens et al.,
1993). The CaLB domain is within amino acids 1522-
1629 of TOR1 and in the corresponding position in
TOR2 and pllO (Figure 3) (Stephens et al., 1993). In-
terestingly, both intracellular Ca2' and the TORs are
required for cell cycle progression in yeast (see below)
(Iida et al., 1990).
TOR1 is leucine rich, and the spacing of the leucines
in amino acids 312-333 is characteristic of a leucine
zipper (Busch and Sassone-Corsi, 1990). However, leu-
cine zippers form alpha helices, and a secondary struc-
ture prediction based on the algorithms of Kyte and
Doolittle (1982) indicates that the potential leucine zip-
per in TOR1 does not have the tendency to form an
alpha helix because of a proline at position 331. TOR2
is also leucine rich but does not have any sequences
resembling a leucine zipper.
TOR1 Is not Essential but Cells Lacking TOR1 and
TOR2 Arrest in the Gi Phase of the Cell Cycle
To determine whether the TORI gene is essential for
cell viability, several disruptions within the TORI ORF
were constructed (Figure 1B). Diploids heterozygous for
each of the disruptions indicated in Figure 1B were
sporulated and dissected. Spores were incubated at 30°C
on rich (YPD) medium. Four viable progeny were ob-
tained in each case, indicating that TORI, in contrast to
TOR2, is not essential for vegetative growth. The torl
segregants grew slightly slower but otherwise behaved
like an isogenic wild-type strain. The generation time
of torl strains grown in YPD liquid cultures at 30°C
was 10-15% longer than that of a wild-type strain. At
high and low temperatures this slow growth phenotype
was slightly accentuated; at 24°C and 37°C, the gen-
eration time of the torl strains was increased 15-25%
compared to a wild-type strain (Figure 6, A and B). This
slow growth is not a petite phenotype (respiratory de-
ficiency) because growth on nonfermentable carbon
sources (YPglycerol, YPpyruvate, YPlactate) was not al-
tered any more than growth on YPD. The torl mutants
also mated normally as assayed by a patch mating assay,
and homozygous torl diploids sporulated as well as an
isogenic wild-type strain. Furthermore, disruption of
TORI did not confer resistance to rapomycin, as ex-
pected. No significant differences in behavior among
strains containing the different disruption alleles shown
in Figure 1B were detected.
Although disruption of TORI alone confers only a
subtle growth defect, it confers a very pronounced phe-
notype when combined with a disruption of TOR2. The
TORI TOR2 double disruption causes cells to arrest
growth in the Gl phase of the cell cycle as previously
determined by a terminal phenotype of large unbudded
cells (Kunz et al., 1993). To characterize further the arrest
caused by TOR depletion, we performed flow cytometry
(FACS analysis) on a wild-type strain (TOR1 TOR2)
and strains lacking TOR1 (torl TOR2), TOR2 (TORI
tor2), or both (torl tor2) (see MATERIALS AND METH-
ODS). Populations of TORI TOR2, torl TOR2, and TORI
tor2 cells exhibited a normal distribution of DNA con-
tent, with approximately equal numbers of cells in the
Gl (in) and G2/M (2n) phase of the cell cycle (Figure
4). The torl tor2 strain showed a DNA distribution typ-
ical of cells arrested in the G1 phase of the cell cycle
(Figure 4). Thus, depletion of both TOR1 and TOR2
causes cells to arrest in the Gl phase of the cell cycle,
as indicated by a terminal phenotype of large unbudded
cells (Kunz et al., 1993) and by a ln DNA content. Fur-
ther analysis is required to define precisely where in G1
the cells are arrested. The FACS analysis also confirms
that strains lacking TOR1 and TOR2 individually do
not have an obvious cell cycle defect.
The above results taken together indicate that TOR1
and TOR2 are structurally and functionally related.
However, the finding that strains lacking either one of
the two TORs have a detectable growth defect (Kunz
et al., 1993) suggests that the functions of TOR1 and
TOR2 are not completely redundant. Alternatively,
growth is stringently controlled by the level of active
TOR protein in the cell.
Figure 4. TOR-depleted cells arrest growth with GI DNA content.
DNA content of haploid strains JK9-3da (TOR1 TOR2), MH349-3d
(torl TOR2), JK350-3a (TORI tor2), and JK350-2a (torl tor2) was de-
termined by flow cytometry (see MATERIALS AND METHODS). Re-
sults are plotted as the relative number of events on the vertical axis
against fluorescence (DNA content) on the horizontal axis. Populations
of TORI TOR2, torl TOR2, and TORI tor2 cells contain both ln (GI,
left-hand peak) and 2n (G2/M, right-hand peak) DNA. Only tori
tor2 cells arrest growth in the Gl phase of the cell cycle, as indicated
by an almost exclusively ln DNA content.
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Because rapamycin resistance can be conferred by
mutations in FPR1, TORI, or TOR2, we examined
whether there is any interplay between disruptions in
these three genes. Strain JH3-3b (fprl::URA3-3) was
crossed with strains MH349-3d (torl ::LEU2-4) and
MH350-la (torl ::LEU2-5). Four viable spores were ob-
tained from the resultant diploids, including segregants
with the two disruption markers, indicating that a torl
fprl combination is not lethal. Strains MH269-4d and
MH272-lc (fprl::URA3-3) were crossed with strain
JK350-3a (tor2::ADE2-3) containing a plasmid-bome
copy of TOR2 (pJK3-3). Dissection of diploids from
which pJK3-3 had been cleared yielded only two viable
spores per tetrad. Approximately one-half of the recov-
ered segregants were Ura+ (fprl:: URA3-3), but all were
Ade- (TOR2), indicating that fprl cannot suppress the
lethality of a TOR2 disruption. Thus, as expected, there
appears to be no genetic interaction between FPR1,
TORI, and TOR2 disruptions.
The Lipid Kinase Domains of TOR1 and TOR2
Are Interchangeable
Our results so far suggest that TOR1 and TOR2 have
common and unique functions. To examine the possible
differences and similarities in the functions of TOR1
and TOR2 and how these functional differences and
similarities might correlate with the structures of the
two proteins, we constructed TOR1-TOR2 and TOR2-
TOR1 hybrids by gene fusion.
A comparison of overlapping fragments of TOR1
against TOR2 revealed three major peaks of identity
corresponding approximately to amino acids 300-1100,
1100-1700, and 1700-2470 (Figure 5). Each peak may
represent a functional and structural domain. Because
the third domain contains the lipid kinase sequence
motif, we constructed the hybrids such that this so-
called lipid kinase domain was reciprocally exchanged
(Figure 5). Taking advantage of a conserved BamHI site
(Figure 2) to construct the hybrid genes, the promoter
region and codons 1-1680 of TORI were fused to co-
dons 1688-2474 and the 3'-end of TOR2 (TOR1-TOR2),
and the promoter region and codons 1-1687 of TOR2
were fused to codons 1681-2470 and the 3'-end of TORI
(TOR2-TOR1) in low copy number (LEU2 CEN4) plas-
mids. The plasmid-encoded hybrid proteins were then
assayed for TOR1 and TOR2 function by complemen-
tation analyses.
To assay for TOR1 and TOR2 function, the hybrid
genes were introduced into a torl ::HIS3-3/TOR1
tor2::ADE2-3/TOR2 heterozygous diploid (SH8), and
the transformed diploids were then sporulated and dis-
sected. TOR2 function was assayed as follows. Because
the tor2::ADE2-3 disruption is lethal, viable Ade+ seg-
regants would be obtained only if a plasmid-borne hy-
brid gene were present (Leu+) and able to provide the
missing TOR2 function. Eighteen tetrads of strain SH8
Amino acid number
1100 1600
TOR1 TOR2
+
n.d. +
B lipid kinase
motif
Figure 5. Distribution of TOR1 to TOR2 identity and structure of
hybrids. Sequential 50% overlapping 200 amino acid fragments of
TOR1 were compared to TOR2 using the Bestfit program (Genetics
Computer Group package, Devereux et al., 1984), and the resultant
percentage values were plotted at the midpoint of each fragment. The
last fragment used was amino acids 2301 to 2470 and was plotted at
position 2400. The region of TOR1 and TOR2 corresponding to the
identity peak containing the lipid kinase motif is referred to as the
lipid kinase domain (amino acid -1700 to the carboxy terminus of
each protein). Structures of TOR1-TOR2 and TOR2-TOR1 hybrids in
which lipid kinase domains were reciprocally exchanged are indicated
below the graph. M represents TOR1 sequence; O represents TOR2
sequence. B indicates the BamHI site used to construct the gene fusions.
The position of the lipid kinase motif is indicated. + and - refer to
function. n.d., not determined.
containing the TOR2-TOR1 hybrid (SH8/pTOR2-
TOR1) were dissected; 15 Ade+ segregants were ob-
tained, all of which were Leu+, indicating that the
TOR2-TOR1 hybrid had TOR2 function. Thirty one tet-
rads of SH8/pTOR1-TOR2 were dissected; no Ade+
segregants were obtained even though in several cases
the plasmid could be inferred to have segregated with
Ade+, indicating that the TOR1-TOR2 hybrid did not
have TOR2 function (Figure 5).
TOR1 function was assayed as follows. Because tor2
(tor2: :ADE2-3) segregants undergo three to four rounds
of division before arresting growth randomly in the cell
cycle and torl tor2 (torl:: HIS3-3 tor2:: ADE2-3) segre-
gants germinate but remain arrested in Gi (Kunz et al.,
1993), we could assay the TOR1-TOR2 hybrid for TOR1
function by monitoring microscopically the segregants
of SH8/pTOR1-TOR2 for number of cell divisions and
the cell cycle arrest point. Ten segregants of SH8/
pTOR1-TOR2 inferred to be disrupted for both TORI
(torl::HIS3-3) and TOR2 (tor2::ADE2-3) and to contain
TOR1-TOR2 expressed from the LEU2 CEN4 plasmid
(inferred His+ Ade+ Leu+), underwent three to five
rounds of division and arrested randomly in the cell
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cycle. Segregants inferred to be torl tor2 and to lack the
hybrid (His' Ade+ Leu-) arrested as single unbudded
cells, as expected. Thus, the TOR1-TOR2 hybrid had
TOR1 function (Figure 5). We could not assay the TOR2-
TOR1 hybrid for TOR1 function in this manner because
this hybrid has TOR2 function and the relevant segre-
gants therefore lack only TOR1 that does not prevent
growth.
To examine further the hybrids for TOR1 function,
we determined whether the hybrids could suppress the
slow growth phenotype of a torl mutant. The low copy
number (LEU2 CEN4) plasmids bearing the hybrid genes
or an intact TOR2 gene were transformed into torl strain
MH353-2b (torl::ADE2-6). As shown in Figure 6, the
TOR1-TOR2, TOR2-TOR1, and TOR2 genes could all
complement the torl mutation and suppress the slow
growth (small colony) phenotype. This suggested that
the TOR1-TOR2 hybrid had TOR1 function, as seen
previously, and that increased dosage of TOR2, either
as a TOR2-TOR1 hybrid or as intact TOR2, could also
provide TOR1 function. However, because intact TOR2
can provide TOR1 function in this assay and in a similar
assay with a torl tor2 strain, we are hesitant to conclude
that TOR2-TOR1 can indeed provide TOR1 function.
For reasons that we cannot yet explain, suppression of
the slow growth phenotype of a torl mutation with
plasmid-borne TOR2 or TOR2-TORI is not a sufficiently
sensitive assay to distinguish TOR1 function from TOR2
function. Thus, we were unable to determine with this
assay or the one described above whether the TOR2-
TOR1 hybrid has TOR1 function.
The above results (Figure 5) indicate that the carboxy-
terminal lipid kinase domains of TOR1 and TOR2 are
interchangeable and therefore functionally equivalent.
The lipid kinase domains of TOR1 and TOR2 have a
function, as strongly suggested by the consensus se-
quence, because lesions in these regions abolish TOR
activity (Figure 1) (Kunz et al., 1993). Because the amino-
terminal segment and/or upstream regions (promoter
and untranslated regions) of each hybrid determines
whether it behaves as TOR1 or TOR2, one or both of
these elements is not interchangeable and therefore not
functionally equivalent.
The TOR1-TOR2 and TOR2-TOR1 Hybrids Are
Targets of Rapamycin
Because TORI and TOR2 were originally identified by
mutations that confer resistance to rapamycin, a shared
function of the two proteins is presumably their ability
to interact directly with and to be inhibited by FKBP-
rapamycin. To probe further the structure and function
of the hybrids, we examined whether their activity was
rapamycin sensitive. torl tor2, TORI tor2, and torl TOR2
segregants of SH8 containing the plasmid-borne TOR2-
TORI gene and torl TOR2 segregants of SH8 expressing
the TOR1-TOR2 hybrid were sensitive to rapamycin
B
A C
Figure 6. Suppression of the torl slow growth phenotype by hybrid
TOR genes. Strains were incubated at 24°C for 60 h on YPD. (A)
MH353-2b/YCplacl 11 (torl TOR2). (B) MH272-lda/YCplacl 11
(TORI TOR2). (C) MH353-2b/pTORl-TOR2 (torl TOR2/TOR1-
TOR2). (D) MH353-2b/pTOR2-TOR1 (torl TOR2/TOR2-TOR1). (E)
MH353-2b/pJK4 (torl TOR2/TOR2).
(0.2 ,ug/ml). This sensitivity was indistinguishable from
that of a wild-type TORI TOR2 strain. Thus, the hybrids
were structurally and functionally intact as targets of
FKBP-rapamycin.
The TORl-1 and TOR2-1 Mutations Alter the Same
Potential PKC Site in Each Protein's
Lipid Kinase Domain
To identify the position of the TORI-i mutation, a
TOR2-TORI hybrid similar to the one described above
was constructed with TORI-i DNA. The TOR2-TORI-
1 hybrid conferred rapamycin resistance, unlike the
wild-type TOR2-TORI hybrid, indicating that the TORI-
I lesion was promoter-distal to the BamHI site (Figure
2) used for construction of the hybrids. To map further
the TORi-i mutation, deletion variants and subclones
of TORi-i (Figure 1A) were assayed for their ability to
transfer the TORi-i lesion to a wild-type chromosomal
TORI allele by in vivo recombination. Haploid strain
JK9-3d transformed with plasmid-borne fragments of
TORi-i were incubated on YPD medium containing ra-
pamycin and examined for papillation of rapamycin-
resistant colonies. The appearance of rapamycin-resis-
tant colonies at high frequency indicated that the plas-
mid-borne TORi-I fragment being tested contained the
lesion and was able to regenerate an intact TORi-i al-
lele. This papillation assay placed the TORI-i mutation
within - 1 kb of the BamHI site. Nucleotide sequence
of the 1-kb region promoter-distal to the BamHI site
revealed a C to A transversion changing serine1972 in
the TOR1 lipid kinase domain to arginine (Figures 2
and 7). Serine,972 is followed by an arginine and is
therefore possibly phosphorylated by PKC. Mammalian
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Figure 7. Alteration of the same potential PKC site in the lipid kinase
domain of TOR1 (TORi-1) or TOR2 (TOR2-1) confers rapamycin
resistance. PKC reacts preferentially with serine followed by lysine
or arginine in the +1 or +2 position (Kishimoto et al., 1985; Woodgett
et al., 1986).
PKC reacts preferentially with serine followed by lysine
or arginine in the +1 or +2 position (Kishimoto et al.,
1985; Woodgett et al., 1986), and mammalian-like PKC
isozymes have been described in yeast (Levin et al.,
1990; Simon et al., 1991; Riedel et al., 1993).
Because the potential PKC site altered in TORl-1 is
also present at the corresponding position in the TOR2
lipid kinase domain (serine,975-arginine) (Figures 3 and
7), we examined whether this site is also altered in the
rapamycin resistance-conferring TOR2-1 allele (Heitman
et al., 1991a). The sequence of the relevant region of
the previously cloned TOR2-1 allele (Kunz et al., 1993)
was determined, and the PKC site was indeed found to
be mutated. The TOR2-1 allele contains a G to T trans-
version in the middle position of codon 1975, changing
serine,975 to isoleucine. Thus, the TORI-i and TOR2-1
mutations eliminate the same serine in the respective
protein's lipid kinase domain; both serines may be
phosphorylated by PKC. Interestingly, the TORs and
PKCs (mammalian a, ,B and y isozymes) both have a
CaLB domain, suggesting that both are translocated to
a membrane in a Ca2+-dependent manner.
We examined whether the TORs are in the same
pathway as PKC1, a yeast homologue of the Ca2+-de-
pendent isozymes of mammalian PKC (Levin et al.,
1990). Because loss of PKC1 results in a cell lysis defect
that is suppressed by osmotic stabilizing agents (Levin
et al., 1992), we first examined whether 1 M sorbitol
has any effect on growth of a wild-type strain and TOR
mutant strains in the presence and absence of rapa-
mycin. One molar sorbitol had no effect on the sensi-
tivity of a wild-type strain (JK9-3d) or on the resistance
of TORl-i (Ri), TOR2-1 (R17), andfprl (JH3-3b) strains
to rapamycin (0.2 jig/ml). The lethality of a TOR2 dis-
ruption was likewise not affected by 1 M sorbitol; TORI
tor2 (JK350-3a) and torl tor2 (JK350-2a) strains con-
taining plasmid-borne TOR2 under control of the GALl
promoter (pJK5) (Kunz et al., 1993) failed to grow on
glucose media with or without 1 M sorbitol. Growth of
a TORI disruption strain (MH349-3d) was also unal-
tered by 1 M sorbitol. We next examined whether PKC1
disruption or overexpression confers rapamycin resis-
tance. PKCl disruption strain DL164 (Levin et al., 1990)
grown in the presence of 1 M sorbitol was sensi-
tive to rapamycin. Strain DL164 containing plasmid-
borne PKC1 under control of the GALl promoter
(pBM743[PKC1]) was also sensitive to rapamycin in the
presence of galactose. Thus, PKC1 does not appear to
act on TOR1 or TOR2 nor to have a role in a rapamycin
sensitive pathway. The TORs may be targets of other
more recently described but not yet cloned mammalian-
like, Ca2"-dependent PKCs (Simon et al., 1991; Riedel
et al., 1993).
DISCUSSION
The TORI and TOR2 genes of S. cerevisiae were origi-
nally identified by mutations that render cells resistant
to the immunosuppressant rapamycin. Here we describe
the cloning and characterization of TORI. The predicted
TOR1 protein is 281 kDa (2470 amino acids) and 67%
identical to TOR2 (2474 amino acids). TOR1 and TOR2,
in turn, are homologous to the p110 catalytic subunit
of bovine PI 3-kinase and the yeast VPS34 PI 3-kinase
(Herman and Emr, 1990; Hiles et al., 1992; Kunz et al.,
1993). All four proteins contain a carboxy-terminal lipid
kinase motif. TOR1, TOR2, and pllO contain a CaLB
domain (Clark et al., 1991; Stephens et al., 1993). Dis-
ruptions of TORI and TOR2 indicate that either TOR1
or TOR2 is required for progression through the Gl
phase of the cell cycle (Kunz et al., 1993).
Four observations suggest that TOR1 and TOR2 have
a common function. First, TORI and TOR2 disruptions
are synergistic. Second, both proteins are targets of ra-
pamycin. Third, the two proteins are highly homolo-
gous, particularly in the carboxy-terminal lipid kinase
domain. Fourth, as observed earlier, specific rapamycin
resistance-conferring alleles of TORI and TOR2 do not
complement each other (nonallelic noncomplementa-
tion) (Heitman et al., 1991a). Other observations suggest
that the common function of TOR1 and TOR2 is a sim-
ilar, cell cycle-related, rapamycin-sensitive PI kinase
activity. First, both a TORI TOR2 double disruption and
exposure to rapamycin cause cells to arrest in the G1
phase of the cell cycle. Second, TOR1 and TOR2 are
homologous to PI kinases, enzymes frequently impli-
cated in control of the cell cycle. Third, the lipid kinase
domains of TOR1 and TOR2 are interchangeable and
therefore functionally equivalent. Lastly, mutations that
make TOR1 and TOR2 resistant to rapamycin alter a
site in the lipid kinase domain of each protein. Thus,
the TORs appear to be similar PI kinases, possibly PI
3-kinases, that may signal the cell to transit through G1.
It remains to be determined what type of cell cycle-
related PI kinase TOR1 and TOR2 may be. Although
some of the early studies on the physiological role of
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different phosphorylated phosphoinositides in yeast are
difficult to interpret because they predate the discovery
of PI 3-kinase (Whitman et al., 1988; Auger et al., 1989a),
several observations have implicated PI 3-kinase, PI 4-
kinase, and PI 5-kinase in the control of the yeast cell
cycle. Activation of a sterol auxotroph by addition of
ergosterol coincides with an increase in PI-4-P (Dahl et
al., 1987). Activation of Gl-arrested yeast cells by ad-
dition of glucose correlates with an increase in the levels
of PI-4-P and PI-3-P (Hawkins et al., 1993). The syn-
thesis of DAG and IP3 (via PI-4-P) is not stimulated by
glucose (Schomerus and Kiintzel, 1992), but the break-
down of PI-4,5-P2 to DAG and IP3 has been shown to
be required for proliferation of yeast cells (Uno et al.,
1988). The lack of detectable PI-3-P in the vacuolar
sorting mutant vps34 does not preclude the existence of
a cell cycle-related PI 3-kinase (Schu et al., 1993). PI 3-
kinases other than VPS34 may occur in much lower
abundance than VPS34 or may be activated only in
response to a specific signal. Furthermore, a cell cycle-
related PI 3-kinase may have a product other than PI-
3-P such that the absence of PI-3-P would not be rel-
evant when considering the cell cycle. Hawkins et al.
(1993) have detected a molecule in yeast similar to PI-
3,4-P2. Three previously identified PI 4-kinases do not
necessarily preclude the existence of two more such ki-
nases either (Buxeda et al., 1991; Flanagan and Thorner,
1992; Nickels et al., 1992). Efforts to determine what
type of PI kinase the TORs might be have so far been
inconclusive.
Although similar, the two TORs are also different be-
cause neither TOR can completely compensate for the
loss of the other; disruptions of TORI and TOR2 indi-
vidually confer different growth defects. The two TORs
could be different qualitatively or quantitatively. How-
ever, we believe the difference must, at least in part, be
qualitative because even increased dosage of TOR1
cannot compensate for loss of TOR2; the TORI gene
on a high copy number plasmid cannot rescue a tor2
mutant. Furthermore, TORI and TOR2 mRNA levels
are similar and constant throughout the cell cycle
(Schneider and Hall, unpublished data). Qualitative dif-
ferences between TOR1 and TOR2 could be, for ex-
ample, differences in regulation (posttranscriptional) or
cellular localization. Alternatively, either or both pro-
teins could have a function unrelated to the proteins'
presumed PI kinase activity. Because the regions of
TORI and TOR2 other than that encoding the lipid ki-
nase domain are not interchangeable, we anticipate that
these regions are responsible for the functional differ-
ence(s) between TOR1 and TOR2.
The finding that the rapamycin resistance-conferring
TORi-i and TOR2-1 mutations alter the same potential
PKC site in each protein's lipid kinase domain (Figure
7) has interesting implications with regard to rapamycin
action and PI kinase function. Assuming the mutated
serine,972 and serine,975 are indeed phosphorylated and
loss of the phosphoserine is responsible for rapamycin
resistance, two models can be envisaged for drug action.
First, the FKBP-rapamycin complex could inhibit a
phosphoserine phosphatase that normally activates
TOR by removal of the phosphate from serine1972 in
TOR1 and from serine1975 in TOR2. This is similar to
the action of the FKBP-FK506 complex in inhibiting the
serine/threonine phosphatase calcineurin in yeast and
mammalian cells (Liu et al., 1991; Foor et al., 1992;
Schreiber, 1992); FK506 is a structural analogue of ra-
pamycin and is also an immunosuppressant. Inherent
in this model is that TOR activity (presumably PI kinase
activity) is negatively regulated by serine phosphory-
lation, as previously observed for mammalian PI 3-ki-
nase (Carpenter et al., 1993). However, because TORI-
1 or TOR2-1 does not confer a growth defect, TOR is
also regulated in some other manner, or a constitutively
active TOR does not have a deleterious effect on the
cell cycle. According to the second model, FKBP-rapa-
mycin inhibits TOR by binding directly and specifically
to the phosphoserine residues in TOR1 and TOR2. This
would be analogous to the specific binding of SH2 do-
mains to phosphotyrosine residues in receptor protein-
tyrosine kinases (Pawson and Schlessinger, 1993).
FKBP-rapamycin may competitively inhibit TOR by
preventing the binding of a yet-to-be identified activator
molecule that normally binds the TOR phosphoserines.
Alternatively, FKBP-rapamycin does not mimic another
molecule but simply inhibits TOR noncompetitively.
Although we do not yet know whether TOR1 or TOR2
are indeed phosphorylated, both mammalian PI 3-ki-
nase and the yeast PI 3-kinase VPS34 appear to be reg-
ulated by phosphorylation. Mammalian PI 3-kinase is
serine/threonine and tyrosine phosphorylated. Serine
phosphorylation by a tightly associated serine/threo-
nine kinase negatively regulates mammalian PI 3-kinase
activity in vitro, and tyrosine phosphorylation likely
mediates regulatory interactions with other proteins
(Cantley et al., 1991; Carpenter et al., 1993; Kavanaugh
et al., 1993; Reif et al., 1993; Stephens et al., 1993).
VPS34 is activated by the associated serine/threonine
kinase VPS15 (Stack et al., 1993). Should serine1972 of
TOR1 and serine1975 of TOR2 not be phosphorylated,
the simplest model for rapamycin action is that FKBP-
rapamycin binds directly to TOR and these serines are
important for such an interaction.
Why should yeast have two similar but not identical
PI kinases? The yeast cell cycle is activated in response
to different and simultaneous environmental cues. Un-
less nutrients are available and a critical cell size has
been attained, a cell remains arrested in Gl. Each of
these different signals could be relayed through a dif-
ferent PI kinase. Different PI kinases could thus be re-
quired to act in concert for optimal production of a sec-
ond messenger needed to activate the cell cycle.
Although we can only speculate as to the answer to the
above question, it is worth noting that there are, also
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for unknown reasons, two forms of both the p85 reg-
ulatory subunit and the p110 catalytic subunit of PI 3-
kinase in mammalian cells (Carpenter et al., 1990; Otsu
et al., 1991; Hiles et al., 1992; Reif et al., 1993).
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